Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.78 |
| ▸ | NPC1 | O15118 | 3/20 | 0.78 |
| ▸ | RAB9A | P51151 | 3/20 | 0.78 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.68 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.59 |
| ▸ | TP53 | P04637 | 2/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | HTT | P42858 | 1/20 | 0.58 |
| ▸ | GFER | P55789 | 1/20 | 0.58 |
| ▸ | DRD3 | P35462 | 7/20 | 0.48 |
| ▸ | DRD2 | P14416 | 5/20 | 0.48 |
| ▸ | DRD4 | P21917 | 3/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31276791 | 1.00 | MAPT (0.78) | MAPTNPC1RAB9ALOXL2SMN1; SMN2 | |
| SCHEMBL5693569 | 0.89 | MAPT (0.72) | MAPTNPC1RAB9ALOXL2SMN1; SMN2 | |
| SCHEMBL155002 | 0.88 | MAPT (1.00) | MAPTNPC1RAB9ALOXL2SMN1; SMN2 | |
| SCHEMBL5703655 | 0.87 | MAPT (0.70) | MAPTNPC1RAB9ALOXL2SMN1; SMN2 | |
| SCHEMBL6206772 | 0.86 | NPC1 (0.68) | MAPTNPC1RAB9ALOXL2SMN1; SMN2 | |
| SCHEMBL11399187 | 0.84 | MAPT (0.84) | MAPTNPC1RAB9ALOXL2SMN1; SMN2 | |
| SCHEMBL2125047 | 0.84 | NPC1 (0.70) | MAPTNPC1RAB9ALOXL2SMN1; SMN2 | |
| SCHEMBL9642061 | 0.84 | MAPT (0.84) | MAPTNPC1RAB9ALOXL2SMN1; SMN2 | |
| SCHEMBL4482992 | 0.81 | LOXL2 (1.00) | MAPTNPC1RAB9ALOXL2SMN1; SMN2 | |
| SCHEMBL31276277 | 0.81 | MAPT (0.78) | MAPTNPC1RAB9ALOXL2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120113809-A | Composite fermentation inulin brewing beverage and preparation process thereof | 山东息壤生物科技发展有限公司 | 2025-06-10 | — | — | CN | claimed |
| CN-115872930-A | N-substituted 3,4-dihydroisoquinoline-1 (2H) -ketone derivative, composition thereof and application thereof in medicines | 贵州医科大学 | 2023-03-31 | — | — | CN | claimed |
| CN-120113809-A | Composite fermentation inulin brewing beverage and preparation process thereof | 山东息壤生物科技发展有限公司 | 2025-06-10 | — | — | CN | disclosed |
| US-20240336868-A1 | COMPOSITIONS COMPRISING ADAMANTYL ESTER-CONTAINING COMPOUNDS | THE PROCTER & GAMBLE COMPANY | 2024-10-10 | — | — | US | disclosed |
| US-20240182463-A1 | SUBSTITUTED POLYCYCLIC CARBAMOYL PYRIDONE DERIVATIVE PRODRUG | SHIONOGI & CO., LTD. (JP) | 2024-06-06 | — | — | US | disclosed |
| US-20230117695-A1 | ARENAVIRUS GROWTH INHIBITOR COMPRISING POLYCYCLIC CARBAMOYL PYRIDONE DERIVATIVE | NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY (JP) | 2023-04-20 | — | — | US | disclosed |
| CN-115872930-A | N-substituted 3,4-dihydroisoquinoline-1 (2H) -ketone derivative, composition thereof and application thereof in medicines | 贵州医科大学 | 2023-03-31 | — | — | CN | disclosed |
| EP-3894416-B1 | FERROPORTIN INHIBITORS AND METHODS OF USE | GLOBAL BLOOD THERAPEUTICS INC (US) | 2022-11-09 | — | — | EP | disclosed |
| EP-3894416-B1 | FERROPORTIN INHIBITORS AND METHODS OF USE | GLOBAL BLOOD THERAPEUTICS INC (US) | 2022-11-09 | — | — | EP | disclosed |
| US-11492352-B2 | Arenavirus growth inhibitor comprising polycyclic carbamoylpyridone derivative | NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY (JP) | 2022-11-08 | — | — | US | disclosed |
| US-11286243-B2 | Ferroportin inhibitors and methods of use | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2022-03-29 | — | — | US | disclosed |
| US-8927710-B2 | Substituted polycyclic carbamoylpyridone derivative | SHIONOGI & CO., LTD. (JP) | 2015-01-06 | — | — | US | disclosed |
| US-20130197219-A1 | SUBSTITUTED POLYCYCLIC CARBAMOYL PYRIDONE DERIVATIVE PRODRUG | SHIONOGI & CO., LTD. (JP) | 2013-08-01 | — | — | US | disclosed |
| EP-2620436-A1 | SUBSTITUTED POLYCYCLIC CARBAMOYL PYRIDONE DERIVATIVE PRODRUG | Shionogi&Co., Ltd. (JP) | 2013-07-31 | — | — | EP | disclosed |
| US-20120184734-A1 | SUBSTITUTED POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE | SHIONOGI & CO., LTD. (JP) | 2012-07-19 | — | — | US | disclosed |
| EP-2444400-A1 | SUBSTITUTED POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE | Shionogi&Co., Ltd. (JP) | 2012-04-25 | — | — | EP | disclosed |
| WO-2005025554-A2 | DIPEPTIDYL PEPTIDASE IV INHIBITOR | JAPAN TOBACCO INC. (JP) | 2005-03-24 | — | — | WO | disclosed |
| US-5149698-A | Pyrimidinyl alkyleneoxy bronchodilator agent | GLAXO GROUP LIMITED (GB) | 1992-09-22 | — | — | US | disclosed |
| US-4996218-A | Bronchodilator, antiulcer agent, cardiovascular disorders | GLAXO GROUP LIMITED (GB) | 1991-02-26 | — | — | US | disclosed |
| EP-0303464-A2 | Chloroaniline derivatives | GLAXO GROUP LIMITED (GB) | 1989-02-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11492352-B2 | Arenavirus growth inhibitor comprising polycyclic carbamoylpyridone derivative | LUC7L2, CXCR6, RRP12 | MAPT 4801/4885NPC1 1486/4885RAB9A 3829/4885 |
| US-20240182463-A1 | SUBSTITUTED POLYCYCLIC CARBAMOYL PYRIDONE DERIVATIVE PRODRUG | PREP, UNG, DPP4 | MAPT 4568/4885NPC1 3250/4885RAB9A 3863/4885 |
| US-20230117695-A1 | ARENAVIRUS GROWTH INHIBITOR COMPRISING POLYCYCLIC CARBAMOYL PYRIDONE DERIVATIVE | CDK7, CCNA1, CCR10 | MAPT 4836/4885NPC1 2071/4885RAB9A 4008/4885 |
| US-20120184734-A1 | SUBSTITUTED POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE | CNBP, ZC3HAV1, DPP4 | MAPT 4280/4885NPC1 2878/4885RAB9A 3087/4885 |
| US-11286243-B2 | Ferroportin inhibitors and methods of use | SLC40A1, HAMP, SFXN1 | MAPT 4429/4885NPC1 360/4885RAB9A 2873/4885 |
| US-20130197219-A1 | SUBSTITUTED POLYCYCLIC CARBAMOYL PYRIDONE DERIVATIVE PRODRUG | PREP, UNG, DPP4 | MAPT 4568/4885NPC1 3250/4885RAB9A 3863/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.